Walleye Trading’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-6,900
| Closed | -$704K | – | 5510 |
|
|
2023
Q2 | $704K | Sell |
6,900
-25,900
| -79% | -$2.45M | ﹤0.01% | 2478 |
|
|
2023
Q1 | $2.98M | Buy |
32,800
+26,800
| +447% | +$1.57M | 0.01% | 1416 |
|
|
2022
Q4 | $228K | Buy |
6,000
+4,600
| +329% | +$158K | ﹤0.01% | 3474 |
|
|
2022
Q3 | $35K | Sell |
1,400
-3,800
| -73% | -$105K | ﹤0.01% | 4326 |
|
|
2022
Q2 | $158K | Buy |
+5,200
| New | +$155K | ﹤0.01% | 3868 |
|
|
2022
Q1 | – | Sell |
-1,000
| Closed | -$26K | – | 6085 |
|
|
2021
Q4 | $26K | Sell |
1,000
-800
| -44% | -$61.9K | ﹤0.01% | 4857 |
|
|
2021
Q3 | $181K | Buy |
1,800
+1,400
| +350% | +$164K | ﹤0.01% | 3959 |
|
|
2021
Q2 | $57K | Buy |
+400
| New | +$45.2K | ﹤0.01% | 4583 |
|
|
2020
Q4 | – | Sell |
-1,600
| Closed | -$156K | – | 5036 |
|
|
2020
Q3 | $156K | Buy |
1,600
+900
| +129% | +$112K | ﹤0.01% | 3162 |
|
|
2020
Q2 | $109K | Buy |
700
+400
| +133% | +$60.8K | ﹤0.01% | 3461 |
|
|
2020
Q1 | $43K | Sell |
300
-8,300
| -97% | -$1.6M | ﹤0.01% | 3468 |
|
|
2019
Q4 | $1.76M | Buy |
8,600
+8,500
| +8,500% | +$1.55M | 0.01% | 1321 |
|
|
2019
Q3 | $8K | Hold |
100
| – | – | ﹤0.01% | 3868 |
|
|
2019
Q2 | $9K | Buy |
+100
| New | +$8.63K | ﹤0.01% | 3846 |
|
|
2019
Q1 | – | Sell |
-1,500
| Closed | -$84K | – | 4941 |
|
|
2018
Q4 | $84K | Buy |
1,500
+600
| +67% | +$36.6K | ﹤0.01% | 3967 |
|
|
2018
Q3 | $74K | Buy |
+900
| New | +$63.4K | ﹤0.01% | 4369 |
|
Other funds holding RETA
Walleye Trading's RETA Position: Q3 2022 in Review
Walleye Trading sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 5,251 shares — an estimated $146K sold.
Walleye Trading first reported a position in RETA in Q4 2016 and held it in 9 quarters. The position peaked at $289K in Q3 2019. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.
- Walleye Trading reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
- Walleye Trading sold 5,251 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $146K.
- Walleye Trading first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2016 and held it in 9 quarters.
- Walleye Trading's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $289K in Q3 2019.
- 159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.
Based on Walleye Trading's 13F filing for Q3 2022, filed 14 Nov 2022.